Details of the Drug

General Information of Drug (ID: DM5YF4M)

Drug Name

Droxidopa

Synonyms

droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-

Indication

Disease Entry	ICD 11	Status	REF
Neurogenic orthostatic hypotension	8D87.0Y	Approved	[1], [2], [3]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

213.19

Topological Polar Surface Area (xlogp)

-3.2

Rotatable Bond Count (rotbonds)

3

Hydrogen Bond Donor Count (hbonddonor)

5

Hydrogen Bond Acceptor Count (hbondacc)

6

ADMET Property

Bioavailability: The bioavailability of drug is 90% [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [5]
Metabolism: The drug is metabolized via the aromatic L-amino acid decarboxylase [4]

Chemical Identifiers

Formula: C9H11NO5
IUPAC Name: (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
Canonical SMILES: C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
InChI: InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
InChIKey: QXWYKJLNLSIPIN-JGVFFNPUSA-N

Cross-matching ID

PubChem CID: 92974
ChEBI ID: CHEBI:31524
CAS Number: 23651-95-8
DrugBank ID: DB06262
TTD ID: D0I3RO
INTEDE ID: DR0552
ACDINA ID: D00219

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
DOPA decarboxylase (DDC)_{Main DME}	DETK9CN	DDC_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Droxidopa (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Droxidopa and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[9]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Droxidopa and Levalbuterol.	Asthma [CA23]	[9]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Droxidopa and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[9]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Droxidopa and LEVONORDEFRIN.	Discovery agent [N.A.]	[9]
Ozanimod	DMT6AM2	Moderate	Additive hypertensive effects by the combination of Droxidopa and Ozanimod.	Multiple sclerosis [8A40]	[10]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Droxidopa 300 mg capsule	300 mg	Oral Capsule	Oral
Droxidopa 100 mg capsule	100 mg	Oral Capsule	Oral
Droxidopa 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7391).
2	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203.
7	Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S1-7.
8	Complexity of dopamine metabolism. Cell Commun Signal. 2013 May 17;11(1):34.
9	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
10	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]